Estrella Immunopharma, Inc. (ESLA) 10-Year Financial Performance & Capital Metrics

ESLA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutEstrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Show more

Revenue $0
EBITDA -$9M -21.6%
Net Income -$9M -21.0%
EPS (Diluted) -0.25 -19.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -400.6% -210.8%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 16 (bottom 16%)
✗Trading more than 30% below 52-week high
✗Expensive at 247.6x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-65.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM82.92%

ROCE

10Y Avg-144.54%

5Y Avg-144.54%

3Y Avg-178.58%

Latest-400.52%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Jun 2022	Dec 2022	Jun 2024	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	1.69M	1.57M	7.31M	8.85M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	296.25K	1.37M	3.2M	2.44M
SG&A % of Revenue	-	-	-	-
Research & Development	1.39M	0	4.11M	6.41M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	201.31K	0	0
Operating Income+	-1.69M	-1.57M	-7.31M	-8.85M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	0.07%	-3.66%	-0.21%
EBITDA+	-1.45M	-1.34M	-7.31M	-8.89M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	0.07%	-4.45%	-0.22%
D&A (Non-Cash Add-back)	236.56K	228.49K	0	-39.59K
EBIT	-247.72K	-915.46K	-7.31M	-8.85M
Net Interest Income+	1.43K	654.07K	0	0
Interest Income	1.43K	654.07K	0	0
Interest Expense	0	0	0	0
Other Income/Expense	1.44M	654.07K	0	0
Pretax Income+	-1.69M	-915.46K	-7.31M	-8.85M
Pretax Margin %	-	-	-	-
Income Tax+	-235.14K	80.65K	1.63K	1.69K
Effective Tax Rate %	1%	1.09%	1%	1%
Net Income+	-1.69M	-996.1K	-7.31M	-8.85M
Net Margin %	-	-	-	-
Net Income Growth %	-	0.41%	-6.34%	-0.21%
Net Income (Continuing)	-247.72K	-996.1K	-7.31M	-8.85M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.29	-0.17	-0.21	-0.25
EPS Growth %	-	0.41%	-0.24%	-0.19%
EPS (Basic)	-0.29	-0.17	-0.21	-0.25
Diluted Shares Outstanding	5.85M	5.76M	35.2M	36.68M
Basic Shares Outstanding	5.85M	5.76M	35.2M	36.68M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Jun 2022	Dec 2022	Jun 2024	Dec 2024
Total Current Assets+	4.92M	52.43K	4.45M	1.64M
Cash & Short-Term Investments	4.09M	40.8K	4.17M	916.92K
Cash Only	4.09M	40.8K	4.17M	916.92K
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	288.76K	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	0	0	0	723.86K
Total Non-Current Assets+	45.19M	9.93M	0	1.5M
Property, Plant & Equipment	0	0	0	0
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	45.19M	9.67M	0	0
Other Non-Current Assets	0	0	0	1.5M
Total Assets+	4.92M	9.99M	4.45M	3.14M
Asset Turnover	-	-	-	-
Asset Growth %	-	1.03%	-0.55%	-0.29%
Total Current Liabilities+	946.68K	1.07M	180.7K	3M
Accounts Payable	945.59K	46.88K	0	0
Days Payables Outstanding	-	-	-	-
Short-Term Debt	0	498.6K	0	0
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	0	8.79M	129.72K	2.98M
Current Ratio	5.20x	0.05x	24.65x	0.55x
Quick Ratio	5.20x	0.05x	24.65x	0.55x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	5.01M	1.84M	0	0
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	292.15K	0	0
Other Non-Current Liabilities	5.01M	1.55M	0	0
Total Liabilities	5.96M	2.92M	180.7K	3M
Total Debt+	0	498.6K	0	0
Net Debt	-4.09M	457.8K	-4.17M	-916.92K
Debt / Equity	-	0.07x	-	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-	-	-	-
Total Equity+	-1.04M	7.07M	4.27M	143.73K
Equity Growth %	-	7.8%	-0.4%	-0.97%
Book Value per Share	-0.18	1.23	0.12	0.00
Total Shareholders' Equity	-1.04M	7.07M	4.27M	143.73K
Common Stock	18	9.33M	3.66K	3.67K
Retained Earnings	-1.07M	-2.26M	-19.5M	-23.93M
Treasury Stock	0	0	-354.44K	-568.92K
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Jun 2022	Dec 2022	Jun 2024	Dec 2024
Cash from Operations+	-1.44M	-1.04M	-16.07M	-7.64M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	0.28%	-14.39%	0.52%
Net Income	-1.69M	-996.1K	-7.31M	-8.85M
Depreciation & Amortization	0	0	0	0
Stock-Based Compensation	129.97K	0	1.19M	0
Deferred Taxes	0	29.47K	0	0
Other Non-Cash Items	-1.43K	-654.07K	0	509.33K
Working Capital Changes	113.35K	576.86K	-9.95M	775.7K
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	0	0	-9.33M	-72.08K
Cash from Investing+	-45.19M	36.17M	4.96M	0
Capital Expenditures	0	0	0	3
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	4.96M	0
Cash from Financing+	5.53M	-35.56M	12.79M	-489.43K
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	530.36K	50K	4.13M	9.58M
Net Change in Cash	-	-	-	-
Free Cash Flow+	-1.44M	-1.04M	-16.07M	-7.64M
FCF Margin %	-	-	-	-
FCF Growth %	-	0.28%	-14.39%	0.52%
FCF per Share	-0.25	-0.18	-0.46	-0.21
FCF Conversion (FCF/Net Income)	0.86x	1.05x	2.20x	0.86x
Interest Paid	0	0	2.66K	0
Taxes Paid	0	0	1.6K	1.6K

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-	-33.03%	-128.91%	-400.6%
Return on Invested Capital (ROIC)	-	-98.08%	-143.59%	-
Debt / Equity	-	0.07x	-	-
FCF Conversion	0.86x	1.05x	2.20x	0.86x

Frequently Asked Questions

Growth & Financials

Estrella Immunopharma, Inc. (ESLA) grew revenue by 0.0% over the past year. Growth has been modest.

Estrella Immunopharma, Inc. (ESLA) reported a net loss of $12.1M for fiscal year 2024.

Dividend & Returns

Estrella Immunopharma, Inc. (ESLA) has a return on equity (ROE) of -400.6%. Negative ROE indicates the company is unprofitable.

Estrella Immunopharma, Inc. (ESLA) had negative free cash flow of $4.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener